Health and effects
Cannabinoids and Pain-related outcomes
What studies can tell us about cannabinoids and Pain-related outcomes, including human research, early evidence, and important limits.
The short answer
What does the research say about Pain-related outcomes?
Researchers have studied cannabinoids in connection with Pain-related outcomes. The current literature covers CBD, THC, CBG, and CBN. This page brings together 19 human-study sources, 27 research reviews, and 16 lab, animal, or mechanism sources. It includes 15 specific study findings from 6 sources. The source set includes human research as well as earlier-stage studies. There is no single answer that applies to every cannabinoid, dose, product, or person. 1
Key takeaways
What to know first
- 1
Research on Pain-related outcomes covers CBD, THC, and CBG; those areas should not be combined into one claim. 1
- 2
The source set includes human research as well as earlier-stage studies. 2
- 3
Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3
Research areas
What researchers studied about Pain-related outcomes
These are the main questions represented in the current literature. Each link opens a source used to build the overview.
Human and early-stage research
CBD
Researchers have studied CBD in connection with Pain-related outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 8
Human research included
THC
Researchers have studied THC in connection with Pain-related outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 9
Preclinical and mechanism-focused
CBG
Researchers have studied CBG in connection with Pain-related outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 10
Human and early-stage research
CBN
Researchers have studied CBN in connection with Pain-related outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 11
Human and early-stage research
CBC
Researchers have studied CBC in connection with Pain-related outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 12
Human and early-stage research
THCV
Researchers have studied THCV in connection with Pain-related outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show.
Results extracted so far
What did the studies report?
These summaries appear only when the recorded study outcome is specific enough to reproduce from the linked source. If a source has no result summary here, the result has not been extracted yet; that does not mean the study found no effect.
-
In a randomized placebo-controlled four-way crossover experimental trial involving 20 adults with fibromyalgia and chronic pain, researchers did not detect a difference in spontaneous pain response after cbd-dominant cannabis following 18.4 mg CBD and less than 1 mg THC once by the vapor inhalation route over 3-hour laboratory assessment after one inhalation. The recorded comparator was cannabinoid-free placebo cannabis. 2
Recorded result: No treatment, including the CBD-dominant variety, produced a greater effect than placebo on spontaneous pain.
-
In a randomized placebo-controlled four-way crossover experimental trial involving 20 adults with fibromyalgia and chronic pain, researchers did not detect a difference in electrical pain response after cbd-dominant cannabis following 18.4 mg CBD and less than 1 mg THC once by the vapor inhalation route over 3-hour laboratory assessment after one inhalation. The recorded comparator was cannabinoid-free placebo cannabis. 2
Recorded result: No treatment, including the CBD-dominant variety, produced a greater effect than placebo on electrical pain.
-
In a single-centre randomized triple-blind placebo-controlled parallel trial involving 102 women with surgically confirmed endometriosis, hormonal therapy, and recurrent symptoms, researchers did not detect a difference in mean recurrent endometriosis pain intensity following escalated from 10 mg/day to 150 mg/day, then tapered by the oral route over 10 weeks. The recorded comparator was placebo. 3
Recorded result: End-of-treatment mean pain was 41.6 mm with CBDO and 36.8 mm with placebo; the between-group difference was not significant.
-
In a single-centre randomized triple-blind placebo-controlled parallel trial involving 102 women with surgically confirmed endometriosis, hormonal therapy, and recurrent symptoms, researchers did not detect a difference in rate of at least 30% endometriosis pain reduction following escalated from 10 mg/day to 150 mg/day, then tapered by the oral route over 10 weeks. The recorded comparator was placebo. 3
Recorded result: Approximately 60% in both groups reported at least 30% improvement; between-group differences were not significant.
-
In a single-centre randomized triple-blind placebo-controlled parallel trial involving 102 women with surgically confirmed endometriosis, hormonal therapy, and recurrent symptoms, researchers did not detect a difference in rate of at least 50% endometriosis pain reduction following escalated from 10 mg/day to 150 mg/day, then tapered by the oral route over 10 weeks. The recorded comparator was placebo. 3
Recorded result: Approximately 40% in both groups achieved at least 50% pain reduction; between-group differences were not significant.
-
In a multicenter randomized double-blind placebo-controlled four-arm trial involving 134 adults with multiple sclerosis or spinal cord injury and neuropathic pain and/or spasticity, researchers did not detect a difference in neuropathic pain intensity in multiple sclerosis or spinal cord injury following up to 45 mg/day by the not stated in the PubMed abstract route over 6 weeks followed by a 1-week phaseout. The recorded comparator was placebo. 4
Recorded result: CBD-versus-placebo estimate 0.45 (95% CI -0.47 to 1.38); no significant difference.
-
In a multicenter randomized double-blind placebo-controlled four-arm trial involving 134 adults with multiple sclerosis or spinal cord injury and neuropathic pain and/or spasticity, researchers did not detect a difference in spasticity intensity in multiple sclerosis or spinal cord injury following up to 45 mg/day by the not stated in the PubMed abstract route over 6 weeks followed by a 1-week phaseout. The recorded comparator was placebo. 4
Recorded result: CBD-versus-placebo estimate 0.46 (95% CI -0.74 to 1.65); no significant difference.
-
In a multicenter randomized double-blind placebo-controlled four-arm trial involving 134 adults with multiple sclerosis or spinal cord injury and neuropathic pain and/or spasticity, researchers did not detect a difference in patient global impression of change following up to 45 mg/day by the not stated in the PubMed abstract route over 6 weeks followed by a 1-week phaseout. The recorded comparator was placebo. 4
Recorded result: The abstract reports no significant active-treatment versus placebo difference; no CBD-specific estimate is provided.
-
In a multicenter randomized double-blind placebo-controlled four-arm trial involving 134 adults with multiple sclerosis or spinal cord injury and neuropathic pain and/or spasticity, researchers did not detect a difference in quality of life following up to 45 mg/day by the not stated in the PubMed abstract route over 6 weeks followed by a 1-week phaseout. The recorded comparator was placebo. 4
Recorded result: The abstract reports no significant active-treatment versus placebo difference; no CBD-specific estimate is provided.
-
In a randomized double-blind placebo-controlled crossover clinical trial involving 38 adults with spinal cord injury and chronic neuropathic pain in the primary analysis, researchers reported a decrease in neuropathic pain intensity after spinal cord injury following up to 800 mg/day by the oral route over two 6-week treatment periods separated by a 4-week washout. The recorded comparator was placebo. 5
Recorded result: Active-phase mean 3.82 (SEM 0.23); mean difference versus placebo -0.54 (SEM 0.15; 95% CI -0.88 to -0.21; P<0.001).
-
In a randomized double-blind placebo-controlled four-arm trial involving 115 patients in the intention-to-treat analysis with peripheral neuropathic pain after failure of at least one evidence-based treatment, researchers did not detect a difference in weekly average peripheral neuropathic pain following flexible dosing from 5 to 50 mg by the oral route over 8 weeks. The recorded comparator was placebo. 6
Recorded result: CBD did not reduce pain versus placebo; week-8 CBD effect estimate 1.14 NRS points worse (95% CI 0.11 to 2.19).
-
In a randomized placebo-controlled crossover trial involving 29 adults with symptomatic peripheral neuropathy of the lower extremities, researchers reported a decrease in intense neuropathic pain following 250 mg CBD per 3 fluid ounces; applied dose not stated in the abstract by the topical route over 4 weeks before crossover. The recorded comparator was placebo. 7
Recorded result: The abstract reports a statistically significant reduction versus placebo; no effect estimate or P value is provided.
-
In a randomized placebo-controlled crossover trial involving 29 adults with symptomatic peripheral neuropathy of the lower extremities, researchers reported a decrease in sharp neuropathic pain following 250 mg CBD per 3 fluid ounces; applied dose not stated in the abstract by the topical route over 4 weeks before crossover. The recorded comparator was placebo. 7
Recorded result: The abstract reports a statistically significant reduction versus placebo; no effect estimate or P value is provided.
-
In a randomized placebo-controlled crossover trial involving 29 adults with symptomatic peripheral neuropathy of the lower extremities, researchers reported a decrease in cold sensations associated with peripheral neuropathy following 250 mg CBD per 3 fluid ounces; applied dose not stated in the abstract by the topical route over 4 weeks before crossover. The recorded comparator was placebo. 7
Recorded result: The abstract reports a statistically significant reduction versus placebo; no effect estimate or P value is provided.
-
In a randomized placebo-controlled crossover trial involving 29 adults with symptomatic peripheral neuropathy of the lower extremities, researchers reported a decrease in itchy sensations associated with peripheral neuropathy following 250 mg CBD per 3 fluid ounces; applied dose not stated in the abstract by the topical route over 4 weeks before crossover. The recorded comparator was placebo. 7
Recorded result: The abstract reports a statistically significant reduction versus placebo; no effect estimate or P value is provided.
How strong is the research?
Not every study answers the same question
This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.
Human studies
Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.
Reviews and evidence summaries
Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.
Lab, animal, and mechanism research
Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.
What these studies actually looked at
The research on Pain-related outcomes is not one kind of study. This source set includes 20 animal studies, 18 narrative or expert reviews, 9 systematic reviews or meta-analyses, and 8 clinical studies in people. 3
The recorded populations or models include people or patients (34 sources), animal models (13 sources), and pediatric, adolescent, or developmental context (2 sources). A result from one group or model should not be assumed to apply to another. 4
The most common recorded outcome focus is pain-related outcomes (62 sources), inflammation-related or pain-related outcomes (9 sources), and electrical pain response (1 source). Closely related outcome names can still describe different measurements. 5
Some source records specify doses including 18.4 mg CBD and less than 1 mg THC once (1 source), 250 mg CBD per 3 fluid ounces (1 source), and escalated from 10 mg or day to 150 mg or day, then tapered (1 source). These are descriptions of what researchers tested, not personal dosing instructions. 6
The Pain-related outcomes source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 7
Examples from the literature
What did the studies actually look at?
Each example names the research question and the study details recorded for that source.
narrative or expert review
Applications of Cannabinoids in Neuropathic Pain: An Updated Review.
On this page, this source examines CBG and pain-related outcomes. 1
- Study type
- narrative or expert review
- Outcome focus
- pain-related outcomes
- Evidence stage
- evidence still limited
clinical study in people
An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia.
On this page, this source examines CBD and pain-related outcomes, CBD and spontaneous pain response after CBD-dominant cannabis, and CBD and electrical pain response after CBD-dominant cannabis. 2
- Study type
- clinical study in people
- Population or model
- people or patients and 20 adults with fibromyalgia and chronic pain
- Outcome focus
- pain-related outcomes and spontaneous pain score and other recorded details
- Dose recorded
- 18.4 mg CBD and less than 1 mg THC once
- Evidence stage
- mechanism-focused research and human research
clinical study in people
Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study.
On this page, this source examines CBD and pain-related outcomes, CBD and mean recurrent endometriosis pain intensity, and CBD and rate of at least 30% endometriosis pain reduction and other related questions. 3
- Study type
- clinical study in people
- Population or model
- people or patients and 102 women with surgically confirmed endometriosis, hormonal therapy, and recurrent symptoms
- Outcome focus
- pain-related outcomes and weekly average perceived pain on a visual analogue scale and other recorded details
- Dose recorded
- escalated from 10 mg or day to 150 mg or day, then tapered
- Evidence stage
- human research
clinical study in people
Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.
On this page, this source examines CBD and pain-related outcomes, CBD and neuropathic pain intensity in multiple sclerosis or spinal cord injury, and CBD and spasticity intensity in multiple sclerosis or spinal cord injury and other related questions. 4
- Study type
- clinical study in people
- Population or model
- people or patients and 134 adults with multiple sclerosis or spinal cord injury and neuropathic pain and or or spasticity
- Outcome focus
- pain-related outcomes and patient-reported neuropathic pain intensity and other recorded details
- Dose recorded
- up to 45 mg or day
- Evidence stage
- human research
clinical study in people
High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial.
On this page, this source examines CBD and pain-related outcomes and CBD and neuropathic pain intensity after spinal cord injury. 5
- Study type
- clinical study in people
- Population or model
- people or patients and 38 adults with spinal cord injury and chronic neuropathic pain in the primary analysis
- Outcome focus
- pain-related outcomes and self-reported pain intensity on a 0-to-10 visual analogue scale
- Dose recorded
- up to 800 mg or day
- Evidence stage
- human research
Safety and limits
What should readers keep in mind?
Research on Pain-related outcomes should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2
Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.
Common questions
Questions people ask
Can cannabinoids help with Pain-related outcomes?
Research exists, but there is not one answer for every cannabinoid or product. The source set includes human research as well as earlier-stage studies. 7
Why can studies reach different answers?
Studies may test different cannabinoids, doses, formulations, routes, people, and outcomes. Those differences can change the result. 8
What should I check in a study?
Check whether it studied people, what product and dose it used, what it measured, how long it lasted, and whether safety was reported. 9
Sources
Read the research
The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.
-
1
Applications of Cannabinoids in Neuropathic Pain: An Updated Review. narrative or expert review; evidence still limited PubMed 37824417 DOI 10.1615/critrevtherdrugcarriersyst.2022038592
-
2
An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. clinical study in people; mechanism-focused research; human research PubMed 30585986 DOI 10.1097/j.pain.0000000000001464
-
3
Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study. clinical study in people; human research PubMed 42261989 DOI 10.1177/25785125251413989
-
4
Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. clinical study in people; human research PubMed 37630995 DOI 10.3390/ph16081079
-
5
High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. clinical study in people; human research PubMed 42256679 DOI 10.1016/j.eclinm.2026.103986
-
6
Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. clinical study in people; human research PubMed 36571471 DOI 10.1002/ejp.2072
-
7
The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. clinical study in people; human research PubMed 31793418 DOI 10.2174/1389201020666191202111534
-
8
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. systematic review or meta-analysis; evidence still limited PubMed 35510826 DOI 10.1002/14651858.cd013444.pub2
-
9
Therapeutic Use of Cannabis and Cannabinoids: A Review. narrative or expert review; evidence still limited PubMed 41296368 DOI 10.1001/jama.2025.19433
-
10
Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. narrative or expert review; evidence still limited PubMed 39598860 DOI 10.3390/molecules29225471
-
11
Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. mechanism-focused research PubMed 19679411 DOI 10.1016/j.drugalcdep.2009.06.009
-
12
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited PubMed 21749363 DOI 10.1111/j.1476-5381.2011.01238.x
See all 62 research sources
This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.
- Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. narrative or expert review; evidence still limited / 1 linked research note PubMed 39598860
- Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited / 3 linked research notes PubMed 21749363
- Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. animal study; preclinical research / 1 linked research note PubMed 39322049
- Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. animal study; mechanism-focused research / 2 linked research notes PubMed 41680865
- The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. animal study; preclinical research / 2 linked research notes PubMed 37332213
- The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 33998900
- Therapeutic Effects of Non-Euphorigenic Cannabis Extracts in Osteoarthritis. animal study; preclinical research / 1 linked research note PubMed 35994012
- Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. animal study; preclinical research / 1 linked research note PubMed 34577072
- Applications of Cannabinoids in Neuropathic Pain: An Updated Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 37824417
- Acidic Cannabinoids Suppress Proinflammatory Cytokine Release by Blocking Store-operated Calcium Entry. narrative or expert review; evidence still limited / 1 linked research note PubMed 35910331
- Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. narrative or expert review; evidence still limited / 1 linked research note PubMed 31899693
- Therapeutic potential of acidic cannabinoids: an update. narrative or expert review; evidence still limited / 2 linked research notes PubMed 41545891
- Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study. human research / 2 linked research notes PubMed 41213439
- Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. animal study; preclinical research / 2 linked research notes PubMed 39921943
- Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. cell or laboratory study; mechanism-focused research / 2 linked research notes PubMed 37764262
- Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation. animal study; mechanism-focused research / 2 linked research notes PubMed 41256665
- Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation. animal study; mechanism-focused research / 2 linked research notes PubMed 42139799
- Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 35510826
- Cannabis-based medicines for chronic neuropathic pain in adults. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 29513392
- Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. systematic review or meta-analysis; evidence still limited / 2 linked research notes PubMed 41429020
- Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. clinical study in people; human research / 5 linked research notes PubMed 37630995
- High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. clinical study in people; human research / 2 linked research notes PubMed 42256679
- Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 33561282
- The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. clinical study in people; human research / 5 linked research notes PubMed 31793418
- Cannabinoids: Medical implications. narrative or expert review; evidence still limited / 1 linked research note PubMed 26912385
- Cannabinoids as a Natural Alternative for the Management of Neuropathic Pain: A Systematic Review of Randomized Placebo-Controlled Trials. narrative or expert review; evidence still limited / 1 linked research note PubMed 39445260
- Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. clinical study in people; human research / 2 linked research notes PubMed 36571471
- Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. clinical study in people; human research / 1 linked research note PubMed 18035205
- Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 37648266
- An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. clinical study in people; mechanism-focused research; human research / 3 linked research notes PubMed 30585986
- Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. clinical study in people; human research / 2 linked research notes PubMed 33118602
- Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study. clinical study in people; human research / 4 linked research notes PubMed 42261989
- Therapeutic Use of Cannabis and Cannabinoids: A Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 41296368
- Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 35982439
- Pharmacology of Medical Cannabis. narrative or expert review; evidence still limited / 1 linked research note PubMed 31332738
- Cannabis-based medicines and medical cannabis for adults with cancer pain. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 37283486
- Cannabis-Based Products for Chronic Pain : A Systematic Review. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 35667066
- Practical considerations in medical cannabis administration and dosing. narrative or expert review; evidence still limited / 1 linked research note PubMed 29307505
- Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. narrative or expert review; evidence still limited / 1 linked research note PubMed 34802112
- Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. mechanism-focused research / 3 linked research notes PubMed 19679411
- Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish. cell or laboratory study; evidence still limited / 1 linked research note PubMed 36424484
- Cannabinoids, inflammation, and fibrosis. narrative or expert review; evidence still limited / 1 linked research note PubMed 27435265
- [Marijuana--2000]. narrative or expert review; evidence still limited / 1 linked research note PubMed 11367861
- Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. human research / 1 linked research note PubMed 39835903
- Cannabis: Chemistry, extraction and therapeutic applications. narrative or expert review; evidence still limited / 1 linked research note PubMed 34838836
- In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. animal study; mechanism-focused research / 3 linked research notes PubMed 33230154
- It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. narrative or expert review; evidence still limited / 2 linked research notes PubMed 32899626
- The antinociceptive activity and mechanism of action of cannabigerol. animal study; preclinical research / 1 linked research note PubMed 36916438
- The Pharmacology of Cannabinoids in Chronic Pain. narrative or expert review; evidence still limited / 1 linked research note PubMed 40046175
- Cannabichromene attenuates fracture pain but impairs bone repair in a murine tibial fracture model. animal study; mechanism-focused research / 1 linked research note PubMed 41794091
- Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity. animal study; mechanism-focused research / 1 linked research note PubMed 41322279
- Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain. animal study; mechanism-focused research / 1 linked research note PubMed 36551296
- Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests. animal study; preclinical research / 1 linked research note PubMed 38255191
- Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. animal study; mechanism-focused research / 1 linked research note PubMed 20942863
- Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. animal study; preclinical research / 1 linked research note PubMed 42151379
- The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. animal study; mechanism-focused research / 1 linked research note PubMed 20590571
- The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. animal study; mechanism-focused research / 1 linked research note PubMed 17245367
- Cannabivarin and tetrahydrocannabivarin modulate nociception via vanilloid channels and cannabinoid-like receptors in Caenorhabditis elegans. mechanism-focused research / 1 linked research note PubMed 41135090
- Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry. human research / 1 linked research note PubMed 30350275
- The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. narrative or expert review; evidence still limited / 1 linked research note PubMed 22155112
- Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy-induced peripheral neuropathy. animal study; mechanism-focused research / 1 linked research note PubMed 35899583
- Chronic Cannabigerol as an Effective Therapeutic for Cisplatin-Induced Neuropathic Pain. animal study; preclinical research / 1 linked research note PubMed 37895913